Table 3:

Associations between SHS exposure (defined using self-report and measured plasma cotinine (>0.05 ng/mL or above the limit of quantification if higher than 0.05 ng/mL)) and asthma outcomes.

Asthma outcomes	OR (95% CI)
	Self-reported exposure*	Plasma cotinine determined exposure
Asthma exacerbations in the previous 12 months†	1.08 (0.75 – 1.57)	1.40 (1.03 – 1.89)
Hospitalizations	1.77 (0.79 – 3.95)	1.26 (0.60 – 2.67)
ER visits	1.21 (0.70 – 2.09)	1.07 (0.65 – 1.75)
Oral steroid prescription	1.00 (0.71 – 1.41)	1.54 (1.18 – 2.04)
Asthma control (binary outcome)‡	1.62 (1.09 – 2.38)	1.53 (1.12 – 2.13)
Not well controlled vs controlled	1.43 (0.93 – 2.21)	1.39 (0.98 – 1.98)
Very poorly controlled vs controlled	1.79 (1.18 – 2.70)	1.67 (1.18 – 2.36)

^*Self-reported exposure to SHS was determined as any vs no reported current smokers in the household.

^†Asthma exacerbations assessed as a combined variable for any exacerbations (hospitalizations, ER visits, prescription of oral steroids) vs none

^‡Asthma control assessed as binary outcome with a combined “not well controlled” and “very poorly controlled” category compared to controlled asthma